Diagnostic performance of FAPI PET/CT for the detection of peritoneal metastases: an updated systematic review and bivariate meta-analysis.

Eur J RadiolJun 16, 2026 (epub)

Wan Qi-Chang, Min Kai-Yin, Wang Cheng-Yi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and bivariate meta-analysis evaluated the diagnostic accuracy of FAPI PET/CT for detecting peritoneal metastases (PM) in cancer patients. The analysis included 15 studies with 837 patients. The pooled sensitivity for patient-based analysis was 97% (95% CI, 91-99%), and for lesion-based analysis, it was 92% (95% CI, 83-96%).

Key findings

  • Pooled sensitivity for patient-based analysis was 97% (95% CI, 91-99%).
  • Pooled specificity for patient-based analysis was 95% (95% CI, 80-99%).
  • Pooled sensitivity for lesion-based analysis was 92% (95% CI, 83-96%).
  • Pooled specificity for lesion-based analysis was 90% (95% CI, 70-97%).

Why it matters

The high sensitivity and specificity of FAPI PET/CT for detecting peritoneal metastases suggest it could be a valuable tool in clinical practice for assessing cancer spread, particularly in high-risk populations.

Source

Published in Eur J Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.